You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent ovarian cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Carcinoma, Survival Outcomes, Adverse Events Trial in Beijing (Niraparib plus anlotinib)

Recruiting
  • Ovarian Carcinoma
  • +8 more
  • Niraparib plus anlotinib
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Ovarian Cancer, Oligometastatic Disease, Recurrent Ovary Cancer Trial (Stereotactic body radiotherapy)

Recruiting
  • Ovarian Neoplasms
  • +2 more
  • Stereotactic body radiotherapy
  • Campobasso, CB, Italy
  • +7 more
Sep 23, 2022

Ovarian Cancer Recurrent Trial in Pittsburgh (Rintatolimod, Pembrolizumab, Cisplatin)

Recruiting
  • Ovarian Cancer Recurrent
  • Pittsburgh, Pennsylvania
    Magee-Womens Hospital of UPMC
Mar 3, 2022

Ovarian Cancer Trial in Copenhagen (APX005M)

Not yet recruiting
  • Ovarian Cancer
  • Copenhagen, Sjaelland, Denmark
    NSGO-CTU
Apr 19, 2022

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer Trial in Australia, Belgium,

Recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • Birmingham, Alabama
  • +14 more
Oct 11, 2022

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Ovarian Cancer Trial in Tampa (Follicle Stimulating Hormone Receptor T Cells)

Recruiting
  • Ovarian Cancer
  • Follicle Stimulating Hormone Receptor T Cells
  • Tampa, Florida
    Moffitt Cancer Center
Mar 30, 2022

Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • +3 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 7, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Ovarian Tumors Trial (Pembrolizumab)

Completed
Has Results
  • Ovarian Neoplasms
  • Pembrolizumab
  • (no location specified)
Feb 23, 2022

Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)

Recruiting
  • Metastatic Breast Cancer
  • Recurrent Ovarian Carcinoma
  • Salt Lake City, Utah
  • +1 more
May 3, 2022

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Ovarian Cancer, Breast Cancer Trial in Vijayawada (Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg)

Recruiting
  • Ovarian Cancer
  • Breast Cancer
  • Olaparib tablets, 150 mg
  • Lynparza® (olaparib) tablets 150 mg
  • Vijayawada, Andhra Pradesh, India
    Sandoz Investigative Site
Apr 12, 2022

Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and

Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Safety of Niraparib in Korean Primary and Recurrent Epithelial

Completed
  • Epithelial Ovarian Cancer
  • Seoul, Korea, Republic of
    Department of Obstetrics and Gynecology, University of Ulsan Col
Oct 11, 2023

Ovarian Cancer Trial in Naples (Olaparib, Chemotherapy drug)

Recruiting
  • Ovarian Cancer
  • Naples, Italy
    IRCCS Istituto Nazionale Tumori di Napoli
Feb 24, 2022

Ovarian Tumors, Ovarian Diseases Trial (Adebrelimab, Fuzuloparib)

Not yet recruiting
  • Ovarian Neoplasms
  • Ovarian Diseases
  • (no location specified)
Feb 23, 2023

Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed

Completed
  • Ovarian Neoplasm
  • +4 more
    • (no location specified)
    Aug 22, 2022

    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

    Not yet recruiting
    • Ovarian Cancer
    • +3 more
    • Beijing, Beijing, China
      Lingying Wu
    Aug 22, 2023

    Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

    Active, not recruiting
    • Fallopian Tube Endometrioid Tumor
    • +13 more
    • Orange, California
    • +19 more
    Jan 10, 2023

    Epithelial Ovarian Cancer Trial (Niraparib)

    Not yet recruiting
    • Epithelial Ovarian Cancer
    • (no location specified)
    May 19, 2022

    Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

    Completed
    • Fallopian Tube Carcinoma
    • +3 more
    • Lenvatinib Mesylate
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 5, 2022

    Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

    Recruiting
    • Recurrent Ovarian Cancer
    • Platinum-sensitive Ovarian Cancer
    • Simvastatin 40mg
    • Los Angeles, California
      Cedars Sinai Medical Center
    Apr 21, 2022

    Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

    Not yet recruiting
    • Ovarian Cancer
    • Malignant Neoplasm of Uterus
    • New York, New York
      Icahn School of Medicine at Mount Sinai Division of Hematology a
    Sep 14, 2023